Impact of Peritoneal Dialysis Treatment on Arterial Stiffness and Vascular Changes in Diabetic Type 2 and Nondiabetic Patients with End-Stage Renal Disease

Table 1

Baseline characteristics of the patients before and after 12 months on PD treatment.

Variable	Without DM		With DM type 2
	Basal	After 12 months	Basal	After 12 months
Age (y)	50.9±17.6		58.3±13.9
Smoking	11 (44.0%)		13.0 (52.0%)
Males	11 (44.0%)		14.0 (56.0%)
SBP (mmHg)	143.0±19.0	130.8±13.2^∗	152.0±20.4^∗∗	137.6±15.1^∗†
DBP (mmHg)	85.6±11.9	75.6±8.2^∗	92.8±12.4^∗∗	83.2±9.9^∗†
BMI (kg/m^2)	24.8±3.4	24.9±2.5	27.1±3.6^∗∗	26.6±2.5^†
Cholesterol (mmol/L)	5.7±1.1	5.3±0.8^∗	7.3±1.7^∗∗	6.53±1.2^∗†
Triglyceride (mmol/L)	2.0±1.3	1.58±0.4^∗	2.8±1.2^∗∗	1.9±0.3^∗†
Albumin (g/L)	32.9±4.5	31.3±2.3	28.5±3.3^∗∗	30.5±2.8^∗
Ca	2.2±0.13	2.2±0.1	2.2±0.21	2.24±0.1
P	1.7±0.3	1.57±0.24^∗	1.82±0.3^∗∗	1.7±0.2^∗
CaxP	3.8±0.68	3.5±0.62^∗	4.0±0.54	3.8±0.6^∗†
PTH	125 (87–267.5)	130 (88.6–210)	259 (181.6–430.0)**	310 (177.5–429.5)^*†
Fibrinogen	5.6±2.1	4.4±1.5^∗	6.7±1.5^∗∗	5.0±1.1^∗†
CRP (mg/dL)	7.3 (3.9–11.9)	3.9 (3.2–6.3)*	13.2 (9.5–21)**	8.1 (5.3–10.5)^*†

∗Significant difference in the same group before (basal) and 12 months after PD treatment.
**Significant difference between groups before the PD treatment.
^†Significant difference between groups 12 months after PD treatment.
SBP: systolic blood pressure; DBP: diastolic blood pressure; BMI: body mass index; Ca: calcium; P: phosphorous; PTH: parathyroid hormone; CRP: C reactive protein.